{"id":"https://openalex.org/W2043928247","doi":"https://doi.org/10.1038/sj.clpt.6100081","title":"Gene Modulatory Effects, Pharmacokinetics, and Clinical Tolerance of Interferon-\u03b11b: A Second Member of the Interferon-\u03b1 Family","display_name":"Gene Modulatory Effects, Pharmacokinetics, and Clinical Tolerance of Interferon-\u03b11b: A Second Member of the Interferon-\u03b1 Family","publication_year":2007,"publication_date":"2007-03-01","ids":{"openalex":"https://openalex.org/W2043928247","doi":"https://doi.org/10.1038/sj.clpt.6100081","mag":"2043928247","pmid":"https://pubmed.ncbi.nlm.nih.gov/17339865"},"language":"en","primary_location":{"id":"doi:10.1038/sj.clpt.6100081","doi":"https://doi.org/10.1038/sj.clpt.6100081","is_oa":false,"landing_page_url":"https://doi.org/10.1038/sj.clpt.6100081","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology &amp; Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5046567271","display_name":"P. Masci","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P Masci","raw_affiliation_strings":["Taussig Cancer Center, Center for Hematology and Oncology Molecular Therapeutics, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA","Taussig Cancer Center Center for Hematology and Oncology Molecular Therapeutics, Cleveland Clinic Foundation, Cleveland, Ohio, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Taussig Cancer Center, Center for Hematology and Oncology Molecular Therapeutics, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA","institution_ids":["https://openalex.org/I1316902750"]},{"raw_affiliation_string":"Taussig Cancer Center Center for Hematology and Oncology Molecular Therapeutics, Cleveland Clinic Foundation, Cleveland, Ohio, USA","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063621818","display_name":"Thomas E. Olencki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T Olencki","raw_affiliation_strings":["James Cancer Center, The Ohio State University, Columbus, Ohio, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"James Cancer Center, The Ohio State University, Columbus, Ohio, USA","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113548771","display_name":"L. Wood","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L Wood","raw_affiliation_strings":["Taussig Cancer Center Center for Hematology and Oncology Molecular Therapeutics, Cleveland Clinic Foundation, Cleveland, Ohio, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Taussig Cancer Center Center for Hematology and Oncology Molecular Therapeutics, Cleveland Clinic Foundation, Cleveland, Ohio, USA","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046052708","display_name":"Lisa A Rybicki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L Rybicki","raw_affiliation_strings":["Department of Biostatistics and Epidemiology , Cleveland Clinic Foundation , Cleveland, Ohio, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistics and Epidemiology , Cleveland Clinic Foundation , Cleveland, Ohio, USA","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024321049","display_name":"Barbara Jacobs","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"B Jacobs","raw_affiliation_strings":["Taussig Cancer Center Center for Hematology and Oncology Molecular Therapeutics, Cleveland Clinic Foundation, Cleveland, Ohio, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Taussig Cancer Center Center for Hematology and Oncology Molecular Therapeutics, Cleveland Clinic Foundation, Cleveland, Ohio, USA","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107976326","display_name":"Bryan R.G. Williams","orcid":"https://orcid.org/0000-0002-4969-1151","observed_orcids":["https://orcid.org/0000-0002-4969-1151","https://orcid.org/0000-0002-8094-1841"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"B Williams","raw_affiliation_strings":["Taussig Cancer Center, Center for Hematology and Oncology Molecular Therapeutics, Cleveland Clinic Foundation Cleveland Ohio USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Taussig Cancer Center, Center for Hematology and Oncology Molecular Therapeutics, Cleveland Clinic Foundation Cleveland Ohio USA","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022706036","display_name":"Pieter W. Faber","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]},{"id":"https://openalex.org/I4405287411","display_name":"Cleveland Clinic Research","ror":"https://ror.org/053229s83","country_code":"US","type":"facility","lineage":["https://openalex.org/I1316902750","https://openalex.org/I4405287411"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P Faber","raw_affiliation_strings":["Department of Cancer Biology, Lerner Research Institute Cleveland Clinic Foundation Cleveland Ohio USA 44195"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Cancer Biology, Lerner Research Institute Cleveland Clinic Foundation Cleveland Ohio USA 44195","institution_ids":["https://openalex.org/I1316902750","https://openalex.org/I4405287411"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112418138","display_name":"Ronald M. Bukowski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R Bukowski","raw_affiliation_strings":["Taussig Cancer Center Center for Hematology and Oncology Molecular Therapeutics, Cleveland Clinic Foundation, Cleveland, Ohio, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Taussig Cancer Center Center for Hematology and Oncology Molecular Therapeutics, Cleveland Clinic Foundation, Cleveland, Ohio, USA","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":null,"display_name":"K Tong","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K Tong","raw_affiliation_strings":["Shanghai Institute of Biologic Products Shanghai China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Shanghai Institute of Biologic Products Shanghai China","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112252438","display_name":"Ernest C. Borden","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E C Borden","raw_affiliation_strings":["Taussig Cancer Center Center for Hematology and Oncology Molecular Therapeutics, Cleveland Clinic Foundation, Cleveland, Ohio, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Taussig Cancer Center Center for Hematology and Oncology Molecular Therapeutics, Cleveland Clinic Foundation, Cleveland, Ohio, USA","institution_ids":["https://openalex.org/I1316902750"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4410,"currency":"USD","value_usd":4410},"apc_paid":null,"fwci":0.2452,"has_fulltext":false,"cited_by_count":15,"citation_normalized_percentile":{"value":0.5752859,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"81","issue":"3","first_page":"354","last_page":"361"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11668","display_name":"interferon and immune responses","score":0.9473000168800354,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11668","display_name":"interferon and immune responses","score":0.9473000168800354,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.009600000455975533,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0034000000450760126,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/interferon-alpha-2","display_name":"interferon alpha 2","score":0.7749999761581421},{"id":"https://openalex.org/keywords/recombinant-interferon","display_name":"recombinant interferon","score":0.8100000023841858},{"id":"https://openalex.org/keywords/ifn-stimulated-genes","display_name":"IFN-stimulated genes","score":0.8579999804496765},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8119999766349792},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.6169999837875366},{"id":"https://openalex.org/keywords/fatigue","display_name":"fatigue","score":0.8899999856948853},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.5830000042915344},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.8579999804496765},{"id":"https://openalex.org/keywords/metastatic-cancer","display_name":"metastatic cancer","score":0.8799999952316284},{"id":"https://openalex.org/keywords/innate-immunity","display_name":"innate immunity","score":0.9020000100135803},{"id":"https://openalex.org/keywords/tumor-necrosis-factor-related-apoptosis-inducing-ligand","display_name":"tumor necrosis factor-related apoptosis-inducing ligand","score":0.8650000095367432},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.5370000004768372}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7944461703300476},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6931215524673462},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6785054206848145},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5951173305511475},{"id":"https://openalex.org/C2776178377","wikidata":"https://www.wikidata.org/wiki/Q188269","display_name":"Interferon","level":2,"score":0.5344535112380981},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.4999558925628662},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.49884700775146484},{"id":"https://openalex.org/C2909179924","wikidata":"https://www.wikidata.org/wiki/Q6046488","display_name":"Alpha interferon","level":3,"score":0.45818156003952026},{"id":"https://openalex.org/C2781228144","wikidata":"https://www.wikidata.org/wiki/Q6046441","display_name":"Interferon alfa","level":4,"score":0.45470932126045227},{"id":"https://openalex.org/C544821477","wikidata":"https://www.wikidata.org/wiki/Q718113","display_name":"Weight loss","level":3,"score":0.41954857110977173},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3659161627292633},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3512986898422241},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3475330173969269},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3323705196380615},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001613","descriptor_name":"beta 2-Microglobulin","qualifier_ui":"Q000096","qualifier_name":"biosynthesis","is_major_topic":false},{"descriptor_ui":"D001613","descriptor_name":"beta 2-Microglobulin","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D001831","descriptor_name":"Body Temperature","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D010597","descriptor_name":"Pharmacogenetics","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D014452","descriptor_name":"Ubiquitins","qualifier_ui":"Q000096","qualifier_name":"biosynthesis","is_major_topic":false},{"descriptor_ui":"D015331","descriptor_name":"Cohort Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015870","descriptor_name":"Gene Expression","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016207","descriptor_name":"Cytokines","qualifier_ui":"Q000096","qualifier_name":"biosynthesis","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D019798","descriptor_name":"Neopterin","qualifier_ui":"Q000096","qualifier_name":"biosynthesis","is_major_topic":false},{"descriptor_ui":"D053221","descriptor_name":"TNF-Related Apoptosis-Inducing Ligand","qualifier_ui":"Q000096","qualifier_name":"biosynthesis","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1038/sj.clpt.6100081","doi":"https://doi.org/10.1038/sj.clpt.6100081","is_oa":false,"landing_page_url":"https://doi.org/10.1038/sj.clpt.6100081","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology &amp; Therapeutics","raw_type":"journal-article"},{"id":"pmid:17339865","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17339865","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology and therapeutics","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G5513620993","display_name":"Clinical and Cellular Effects of Interferon alfa 1","funder_award_id":"R01CA089344","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G8987114368","display_name":"GENERAL CLINICAL RESEARCH CENTER","funder_award_id":"M01RR018390","funder_id":"https://openalex.org/F4320337375","funder_display_name":"National Center for Research Resources"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"},{"id":"https://openalex.org/F4320337375","display_name":"National Center for Research Resources","ror":"https://ror.org/04pw6fb54"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":32,"referenced_works":["https://openalex.org/W82416764","https://openalex.org/W1483828791","https://openalex.org/W1495497204","https://openalex.org/W1524075060","https://openalex.org/W1579629308","https://openalex.org/W1638465953","https://openalex.org/W1828940258","https://openalex.org/W1909639357","https://openalex.org/W1965387829","https://openalex.org/W1978394240","https://openalex.org/W1994629976","https://openalex.org/W1997738769","https://openalex.org/W1998668416","https://openalex.org/W2016986460","https://openalex.org/W2043048841","https://openalex.org/W2063033450","https://openalex.org/W2085237060","https://openalex.org/W2085567621","https://openalex.org/W2095838203","https://openalex.org/W2114913546","https://openalex.org/W2119847512","https://openalex.org/W2120783853","https://openalex.org/W2139248078","https://openalex.org/W2148456822","https://openalex.org/W2160792208","https://openalex.org/W2164743819","https://openalex.org/W2167922599","https://openalex.org/W2222203233","https://openalex.org/W2242666594","https://openalex.org/W2410606281","https://openalex.org/W4231768912","https://openalex.org/W4253729313"],"related_works":["https://openalex.org/W2280055230","https://openalex.org/W193477023","https://openalex.org/W2320399455","https://openalex.org/W2027898486","https://openalex.org/W2415904695","https://openalex.org/W3122717601","https://openalex.org/W1045045433","https://openalex.org/W2173422486","https://openalex.org/W2088556774","https://openalex.org/W2012448707"],"abstract_inverted_index":{"Interferon-alpha1":[0],"(IFN-alpha1),":[1],"which":[2,167],"may":[3],"have":[4],"a":[5,178,236],"primary":[6],"role":[7,239],"in":[8,13,59,78,116,209,218,240,251],"innate":[9,241],"immunity,":[10,242],"differs":[11],"significantly":[12],"amino-acid":[14],"sequence":[15],"from":[16],"IFN-alpha2,":[17],"the":[18,85,155,229],"only":[19],"recombinant":[20,38],"IFN-alpha":[21],"with":[22,27,191,228],"substantial":[23],"clinical":[24,247],"evaluation.":[25],"Patients":[26],"metastatic":[28],"malignancies":[29],"received":[30],"daily":[31],"subcutaneous":[32],"doses":[33],"of":[34,37,55,105,113,130,175,182,212,232,249],"1.5-270":[35],"mug/m(2)":[36],"IFN-alpha1b.":[39],"Gene":[40],"modulation,":[41],"pharmacokinetics,":[42],"tolerability,":[43],"and":[44,52,119,125,134,215,235,254],"disease":[45],"response":[46],"were":[47,98,107,136,141],"determined.":[48],"Significant":[49],"(P<0.01)":[50,82,97],"dose":[51,87,157,169,179],"gene-dependent":[53],"increases":[54,81],"2-10":[56],"fold":[57],"occurred":[58,121],"IFN-stimulated":[60],"genes,":[61],"including":[62,201],"four":[63],"(tumor":[64],"necrosis":[65],"factor-related":[66],"apoptosis-inducing":[67],"ligand,":[68],"cig":[69],"5,":[70],"p56,":[71],"GEM)":[72],"never":[73],"previously":[74],"identified":[75],"as":[76],"increased":[77],"patients;":[79],"significant":[80],"resulted":[83,208],"at":[84,108,154],"lowest":[86],"(1.5":[88],"microg/m(2);":[89],"1.5":[90],"x":[91],"10(4)":[92],"human":[93],"antiviral":[94],"units/m(2)).":[95],"Increases":[96],"sustainable":[99],"for":[100,143,180,198,245],">4":[101],"weeks.":[102],"Peak":[103],"levels":[104],"IFN-alpha1b":[106,207],"3":[109,160],"h;":[110],"an":[111],"increase":[112],"approximately":[114],"eightfold":[115],"both":[117],"C(max)":[118],"AUC":[120],"between":[122],"15":[123],"microg/m(2)":[124],"270":[126,186],"microg/m(2).":[127,187],"Chronic":[128],"toxicities":[129],"anorexia,":[131],"weight":[132,150],"loss,":[133],"fatigue":[135,161,176],"relatively":[137],"uncommon.":[138],"Eighteen":[139],"patients":[140,153,189],"treated":[142],">8":[144],"weeks;":[145],"none":[146],"experienced":[147],">grade":[148],"1":[149],"loss.":[151],"Three":[152],"highest":[156],"developed":[158],"grade":[159],"after":[162],">":[163],"or":[164,171],"=3":[165],"months,":[166],"required":[168],"reduction":[170],"discontinuation.":[172],"Patient":[173],"acceptability":[174],"defined":[177],"initiation":[181],"Phase":[183],"II":[184],"trials,":[185],"Six":[188],"(five":[190],"renal":[192,219],"cell":[193,220],"carcinoma)":[194],"had":[195,204],"progression-free":[196],"survival":[197],">1":[199],"year,":[200],"two":[202],"who":[203],"partial":[205],"responses.":[206],"potent":[210],"stimulation":[211],"IFN-regulated":[213],"genes":[214],"tumor":[216],"regressions":[217],"carcinoma.":[221],"Unique":[222],"gene":[223],"modulatory":[224],"effects,":[225],"when":[226],"coupled":[227],"moderate":[230],"severity":[231],"side":[233],"effects":[234],"potentially":[237],"central":[238],"provide":[243],"rationale":[244],"further":[246],"evaluation":[248],"IFN-alpha1":[250],"virus":[252],"infections":[253],"cancer.":[255]},"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2013,"cited_by_count":3}],"updated_date":"2026-11-01T11:40:01.658920","created_date":"2016-06-24T00:00:00"}